• Presenting phase I data on radiotherapy with PARP inhibitors (olaparib, niraparib) across diverse GBM patient populations

• Detailing insights from first-in-human radiotherapy + ATM inhibitor studies advancing into randomized phase II/III trials

• Affirming preclinical evidence that PARP and ATM inhibitors both radiosensitize GBM tumors and protect healthy brain tissue from radiation-induced cognitive decline